HUE026579T2 - Removal of virus infections from AAV preparations - Google Patents

Removal of virus infections from AAV preparations Download PDF

Info

Publication number
HUE026579T2
HUE026579T2 HUE12758663A HUE12758663A HUE026579T2 HU E026579 T2 HUE026579 T2 HU E026579T2 HU E12758663 A HUE12758663 A HU E12758663A HU E12758663 A HUE12758663 A HU E12758663A HU E026579 T2 HUE026579 T2 HU E026579T2
Authority
HU
Hungary
Prior art keywords
filter
virus
sample
aav
virions
Prior art date
Application number
HUE12758663A
Other languages
English (en)
Hungarian (hu)
Inventor
Wilhelmus Theodorus Johannes Maria Christiaan Hermens
James Patrick Smith
Original Assignee
Uniqure Ip Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47832422&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE026579(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Uniqure Ip Bv filed Critical Uniqure Ip Bv
Publication of HUE026579T2 publication Critical patent/HUE026579T2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D61/00Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14Ultrafiltration; Microfiltration
    • B01D61/145Ultrafiltration
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D61/00Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14Ultrafiltration; Microfiltration
    • B01D61/16Feed pretreatment
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D71/00Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
    • B01D71/06Organic material
    • B01D71/08Polysaccharides
    • B01D71/10Cellulose; Modified cellulose
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02Recovery or purification
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D2311/00Details relating to membrane separation process operations and control
    • B01D2311/04Specific process operations in the feed stream; Feed pretreatment
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D2311/00Details relating to membrane separation process operations and control
    • B01D2311/26Further operations combined with membrane separation processes
    • B01D2311/2623Ion-Exchange
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D2311/00Details relating to membrane separation process operations and control
    • B01D2311/26Further operations combined with membrane separation processes
    • B01D2311/2649Filtration
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/14011Baculoviridae
    • C12N2710/14041Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/14011Baculoviridae
    • C12N2710/14051Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14051Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14311Parvovirus, e.g. minute virus of mice
    • C12N2750/14332Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14311Parvovirus, e.g. minute virus of mice
    • C12N2750/14351Methods of production or purification of viral material

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Water Supply & Treatment (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HUE12758663A 2011-09-08 2012-09-07 Removal of virus infections from AAV preparations HUE026579T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161532176P 2011-09-08 2011-09-08
EP11180594 2011-09-08

Publications (1)

Publication Number Publication Date
HUE026579T2 true HUE026579T2 (en) 2016-06-28

Family

ID=47832422

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE12758663A HUE026579T2 (en) 2011-09-08 2012-09-07 Removal of virus infections from AAV preparations

Country Status (19)

Country Link
US (3) US9840694B2 (enExample)
EP (3) EP2744895B1 (enExample)
JP (2) JP6198278B2 (enExample)
KR (1) KR101961347B1 (enExample)
CN (2) CN107502597A (enExample)
AU (1) AU2012304993B2 (enExample)
BR (1) BR112014005255A2 (enExample)
CA (1) CA2847604A1 (enExample)
DK (1) DK2744895T3 (enExample)
EA (1) EA027511B1 (enExample)
ES (1) ES2558168T3 (enExample)
HU (1) HUE026579T2 (enExample)
IL (1) IL231398A (enExample)
MX (1) MX349601B (enExample)
PL (1) PL2744895T3 (enExample)
PT (1) PT2744895E (enExample)
SI (1) SI2744895T1 (enExample)
WO (1) WO2013036118A1 (enExample)
ZA (1) ZA201401714B (enExample)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2847604A1 (en) 2011-09-08 2013-03-14 Uniqure Ip B.V. Removal of contaminating viruses from aav preparations
CA2927366A1 (en) 2013-10-24 2015-04-30 Uniqure Ip B.V. Aav-5 pseudotyped vector for gene therapy for neurological diseases
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
CN107106689A (zh) 2014-11-05 2017-08-29 沃雅戈治疗公司 用于治疗帕金森病的aadc多核苷酸
KR102584655B1 (ko) 2014-11-14 2023-10-06 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
MX2017006216A (es) 2014-11-14 2018-08-29 Voyager Therapeutics Inc Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela).
HK1244849B (en) * 2014-11-28 2020-04-09 Uniqure Ip B.V. Dna impurities in a composition comprising a parvoviral virion
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
ES2732023T3 (es) 2014-12-24 2019-11-20 Uniqure Ip Bv Supresión del gen de la huntingtina inducida por ARNi
EP3054007A1 (en) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
AU2017268382B2 (en) 2016-05-18 2023-09-28 Voyager Therapeutics, Inc. Compositions and methods of treating Huntington's disease
RU2758488C2 (ru) 2016-05-18 2021-10-28 Вояджер Терапьютикс, Инк. Модулирующие полинуклеотиды
JP2019531787A (ja) 2016-08-30 2019-11-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 生物医学的ターゲティング及びデリバリーの方法並びにそれを実行するための装置及びシステム
WO2018204803A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
AU2018261790B2 (en) 2017-05-05 2024-10-03 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CN111132626B (zh) 2017-07-17 2024-01-30 沃雅戈治疗公司 轨迹阵列引导系统
EP3687582A4 (en) 2017-09-29 2021-07-14 Voyager Therapeutics, Inc. RESCUE OF CENTRAL AND PERIPHERAL NEUROLOGICAL PHENOTYPE OF FRIEDREICH ATAXIA BY INTRAVENOUS ADMINISTRATION
US11434502B2 (en) 2017-10-16 2022-09-06 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (ALS)
EP4454654A3 (en) 2017-10-16 2025-02-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
US12480138B2 (en) 2018-01-17 2025-11-25 MeiraGTx Gene Regulation Limited Modified rAAV capsid protein for gene therapy
MX2020012077A (es) 2018-05-15 2021-03-09 Voyager Therapeutics Inc Composiciones y metodos para el tratamiento de la enfermedad de parkinson.
WO2020053258A1 (en) 2018-09-12 2020-03-19 Uniqure Ip B.V. Rnai induced c9orf72 suppression for the treatment of als/ftd
SG11202103151RA (en) 2018-09-28 2021-04-29 Voyager Therapeutics Inc Frataxin expression constructs having engineered promoters and methods of use thereof
EP3867412A1 (en) * 2018-10-15 2021-08-25 REGENXBIO Inc. Method for measuring the infectivity of replication defective viral vectors and viruses
AU2019385638A1 (en) 2018-11-19 2021-06-03 Uniqure Ip B.V. A companion diagnostic to monitor the effects of gene therapy
WO2020104480A1 (en) 2018-11-19 2020-05-28 Uniqure Biopharma B.V. Adeno-associated virus vectors for expressing fviii mimetics and uses thereof
AU2019382824A1 (en) 2018-11-19 2021-06-03 Uniqure Ip B.V. Method and means to deliver miRNA to target cells
EP3884050A1 (en) 2018-11-19 2021-09-29 uniQure IP B.V. Rnai induced reduction of ataxin-3 for the treatment of spinocerebellar ataxia type 3
CN113631225A (zh) * 2019-01-18 2021-11-09 沃雅戈治疗公司 用于生产aav颗粒的方法和系统
SG11202108614QA (en) 2019-02-15 2021-09-29 Sangamo Therapeutics Inc Compositions and methods for producing recombinant aav
WO2020219897A1 (en) * 2019-04-24 2020-10-29 Biogen Ma Inc. Methods for production of recombinant adeno-associated viruses
HRP20241647T1 (hr) 2019-07-15 2025-02-14 Meiragtx Uk Ii Limited Modificirani proteini aav kapsida za liječenje artritične bolesti
EP4031148A1 (en) 2019-09-16 2022-07-27 uniQure IP B.V. Targeting misspliced transcripts in genetic disorders
CN114981442A (zh) 2019-12-04 2022-08-30 桑格摩生物治疗股份有限公司 用于生产重组aav的新颖组合物及方法
EP4073083A1 (en) * 2019-12-12 2022-10-19 EMD Millipore Corporation Intensified virus filtration using diafiltration buffer
EP4097239A2 (en) * 2020-01-29 2022-12-07 Voyager Therapeutics, Inc. Methods and systems for producing aav particles
JP7390466B2 (ja) * 2020-02-28 2023-12-01 旭化成メディカル株式会社 ウイルスクリアランス性能の評価方法
CA3174872A1 (en) 2020-04-07 2021-10-14 Sander Jan Hendrik Van Deventer Gene constructs for silencing angiopoietin-like 3 (angptl3) and uses thereof
EP4305157A1 (en) 2021-03-09 2024-01-17 Huidagene Therapeutics (Singapore) Pte. Ltd. Engineered crispr/cas13 system and uses thereof
JP2024515027A (ja) * 2021-03-30 2024-04-04 スリーエム イノベイティブ プロパティズ カンパニー 中空糸膜及びその作製方法
WO2022214635A1 (en) 2021-04-08 2022-10-13 Stichting Vu Nucleic acid molecules for compensation of stxbp1 haploinsufficiency and their use in the treatment of stxbp1-related disorders
WO2022253974A1 (en) 2021-06-02 2022-12-08 Uniqure Biopharma B.V. Adeno-associated virus vectors modified to bind high-density lipoprotein
EP4359525A1 (en) 2021-06-21 2024-05-01 uniQure biopharma B.V. Gene constructs for silencing alpha-synuclein and uses thereof
CN117836010A (zh) 2021-06-21 2024-04-05 优尼科生物制药有限公司 改进的裂解程序
WO2023283962A1 (en) 2021-07-16 2023-01-19 Huigene Therapeutics Co., Ltd. Modified aav capsid for gene therapy and methods thereof
US20250223590A1 (en) 2022-04-12 2025-07-10 Uniqure Biopharma B.V. Nucleic acid regulation of ApoE
WO2023198663A1 (en) 2022-04-12 2023-10-19 Uniqure Biopharma B.V. Nucleic acid regulation of snca
US20250230437A1 (en) 2022-04-12 2025-07-17 Uniqure Biopharma B.V. Novel systems for nucleic acid regulation
WO2023198702A1 (en) 2022-04-12 2023-10-19 Uniqure Biopharma B.V. Nucleic acid regulation of c9orf72
US20240209324A1 (en) * 2022-12-22 2024-06-27 Cytiva Us Llc Virus separation
AU2024256392A1 (en) 2023-04-18 2025-10-23 Uniqure Biopharma B.V. Gene delivery vehicles comprising rna and antibodies
AU2024258047A1 (en) 2023-04-18 2025-10-23 Uniqure Biopharma B.V. Novel neurotropic adeno-associated virus capsids with detargeting of peripheral organs
WO2024261220A1 (en) 2023-06-23 2024-12-26 Uniqure Biopharma B.V. Novel fragile x constructs
WO2025051805A1 (en) 2023-09-04 2025-03-13 Uniqure Biopharma B.V. Novel neurotropic recombinant adeno-associated virus particles
WO2025078598A1 (en) 2023-10-11 2025-04-17 Uniqure Biopharma B.V. Novel nucleic acid regulation of huntingtin gene
WO2025078606A1 (en) 2023-10-11 2025-04-17 Uniqure Biopharma B.V. Further novel systems for nucleic acid regulation
WO2025078602A1 (en) 2023-10-11 2025-04-17 Uniqure Biopharma B.V. Nucleic acid regulation of msh3 in repeat expansion disorders
WO2025114524A1 (en) 2023-11-30 2025-06-05 Uniqure Biopharma B.V. Formulations for viral drug products
WO2025219443A1 (en) 2024-04-19 2025-10-23 Uniqure Biopharma B.V. Nucleic acid for a1at regulation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
AU4270196A (en) 1994-10-07 1996-05-02 Lutz Gissmann Papilloma virus-like particles, fusion proteins and process for producing the same
DE19709186C2 (de) * 1997-03-06 1999-10-14 Medigene Ag Filtrationsverfahren zur Trennung von Viren
US6103526A (en) 1998-10-08 2000-08-15 Protein Sciences Corporation Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
AU780231B2 (en) 1998-11-10 2005-03-10 University Of North Carolina At Chapel Hill, The Virus vectors and methods of making and administering the same
US6593123B1 (en) * 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
WO2003074714A1 (en) 2002-03-05 2003-09-12 Stichting Voor De Technische Wetenschappen Baculovirus expression system
US20050009168A1 (en) * 2003-05-12 2005-01-13 Robbins Joan Marie Methods and apparatus for Adeno associated virus purification
US8512981B2 (en) * 2006-06-21 2013-08-20 Amsterdam Molecular Therapeutics B.V. Vectors with modified initiation codon for the translation of AAV-Rep78 useful for production of AAV
WO2008109721A1 (en) * 2007-03-06 2008-09-12 Introgen Therapeutics, Inc. Chromatographic methods for assessing adenovirus purity
US20100323429A1 (en) * 2008-04-10 2010-12-23 Yu-Chen Hu Methods for purifying baculovirus
CN102803478B (zh) * 2009-06-16 2016-04-27 建新公司 用于纯化重组aav载体的改进方法
PT2529020T (pt) * 2010-01-28 2018-07-30 Childrens Hospital Philadelphia Plataforma de fabrico escalável para purificação de vetor viral e vetores virais assim purificados para utilização na terapia génica
CA2847604A1 (en) * 2011-09-08 2013-03-14 Uniqure Ip B.V. Removal of contaminating viruses from aav preparations

Also Published As

Publication number Publication date
US20190218523A1 (en) 2019-07-18
ES2558168T3 (es) 2016-02-02
EP3425044A1 (en) 2019-01-09
CN103857790A (zh) 2014-06-11
EA027511B1 (ru) 2017-08-31
US9840694B2 (en) 2017-12-12
JP2014526246A (ja) 2014-10-06
SI2744895T1 (sl) 2016-03-31
ZA201401714B (en) 2015-12-23
EP2990477B1 (en) 2018-08-29
PL2744895T3 (pl) 2016-04-29
EP2990477A1 (en) 2016-03-02
MX349601B (es) 2017-08-04
EP2744895B1 (en) 2015-10-14
US20140342434A1 (en) 2014-11-20
EP2990477B8 (en) 2018-10-31
US20180100143A1 (en) 2018-04-12
PT2744895E (pt) 2016-02-08
DK2744895T3 (en) 2016-01-04
AU2012304993A1 (en) 2014-03-20
KR101961347B1 (ko) 2019-03-25
MX2014002733A (es) 2014-07-14
EA201490583A1 (ru) 2014-07-30
JP6624690B2 (ja) 2019-12-25
IL231398A0 (en) 2014-04-30
CN107502597A (zh) 2017-12-22
WO2013036118A1 (en) 2013-03-14
KR20140074333A (ko) 2014-06-17
US10253301B2 (en) 2019-04-09
CA2847604A1 (en) 2013-03-14
CN103857790B (zh) 2017-09-08
HK1220229A1 (en) 2017-04-28
BR112014005255A2 (pt) 2017-04-04
AU2012304993B2 (en) 2017-09-14
JP6198278B2 (ja) 2017-09-20
JP2018023365A (ja) 2018-02-15
EP2744895A1 (en) 2014-06-25
IL231398A (en) 2017-06-29

Similar Documents

Publication Publication Date Title
US10253301B2 (en) Removal of contaminating viruses from AAV preparations
AU2005297372B2 (en) Improved viral purification methods
AU2003229159B2 (en) Improved viral purification methods
ES2472429T3 (es) Método para la purificación de partículas de adenovirus a partir de cultivos de alta densidad celular
JP7266306B2 (ja) トリコプルシア・ニの蛹における組み換えタンパク質の発現
Tijssen et al. Parvoviridae. Structure and reproduction of densonucleosis viruses
US20240287545A1 (en) Improved lysis procedures
HK1220229B (en) Removal of contaminating viruses from aav preparations
HK1262994A1 (en) Removal of contaminating viruses from aav preparations
Michalsky et al. Concentration of the baculovirus Autographa californica M nucleopolyhedrovirus (AcMNPV) by ultrafiltration
US20050009168A1 (en) Methods and apparatus for Adeno associated virus purification
Michalsky et al. Purification of the baculovirus Autographa californica M nucleopolyhedrovirus by tangential flow ultrafiltration
JP7588466B2 (ja) パルボウイルスの生産方法
WO2024054983A1 (en) Controlled expression of viral proteins